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ABSTRACT: Asthmatic subjects who are resident at altitude may experience a 
deterioration in lung function following a stay at sea level. To determine whether 
measurement of urinary leukotriene E4 (LTEJ reflects changes in asthma severity 
and airway responsiveness, 14 allergic asthmatic subjects resident at altitude (1560 
m, Davos, Switzerland) were studied.
Subjects were randomly divided into two groups. Measurements of baseline for­
ced expiratory volume in one second (FEV^, the concentration of histamine pro­
ducing a 20% decrease in FEV15 (PC20 FEVj), serum total immunoglobulin E (IgE), 
eosinophil count, and urinary LTE4 concentration were determined prior to a n d  
following a 2 week stay in The Netherlands (sea level) in eight subjects (4 males 
a n d  4 females, aged 14+0.5 yrs) (mean±SEM) and over a similar time period in six 
subjects (4 males and 2 females, aged 15±0.3 yrs) resident in Davos, Switzerland.
There was no significant difference in total IgE and eosinophil count, and no 
significant correlation between urinary LTE4 and PC20FEVt histamine, FEV15 
total IgE, and eosinophil count. In subjects returning to Davos from The Nether­
lands there was a significant increase in urinary LTE4 from a baseline value of 16.9 
pg’Dig-* creatinine (gm, range 0.3-101.7 pg-mg-1 creatinine) to 52.3 pg-mg'1 creati­
nine (gm, range 8.8-301.6 pg-mg4 creatinine), a significant decrease in PCiOFEVj 
from 1.7 mg*mW (gm , range 0.3-16.4 mg*ml !) to 0.9 mg-ml1 (gm , range 0.1->32  
mg*mF), and a significant fall in FEV1 from 3.0±0.3 to 2.8±0.3 I  (m ean±SEM ). There 
w a s  no significant change in urinary LTE4, FEVj or PC20FEV, histamine during a 
similar period of time in subjects resident in Davos.
Thus, following a visit to sea level, children with atopic asthma who are usu­
ally resident at altitude exhibit a fall in FEVj and an increase in airway respon­
siveness to histamine, which is associated with a threefold increase in urinary LTE4 
excretion.
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The cysteinyl leukotrienes (LTC4, LTD4 and LTE4) 
are derived from arachidonic acid by the action of 5- 
lipoxygenase, which generates 5-hydroperoxyeicosate- 
traenoic acid and then leukotriene A4 (LTA4) [1—3]. LTA4 
is metabolized by the addition of glutathione to form 
LTC4. LTC4 may be converted by y-glutamyltranspep- 
tidase to generate LTD4, which is converted by a di­
peptidase to yield LTE4 [4, 5]. In vitro the cysteinyl 
leukotrienes, LTC4, LTD4 and LTE4, contract smooth 
muscle and enhance micro vascular permeability [6-8]. 
In humans they are potent bronchoconstrictor agents 
when inhaled, and increase nonspecific bronchial hyper­
responsiveness [9-12].
In man, there is rapid metabolism of LTC4 to LTD4 
and then to LTE4. LTE4 may be further metabolized to 
oxidation products, which are excreted into bile and urine
[13-16]. Combined reversed-phase high performance 
liquid chromatography (RP-HPLC) and radioimmuno­
assay (RIA) enables urinary LTE4 to be measured [17], 
and the values have been used as an estimate of the pro­
duction of cysteinyl leukotrienes in vivo. An increase 
in LTE4 excretion occurs during an acute exacerbation 
of asthma, after antigen challenge in allergic asthmatic 
subjects [18-22], and following aspirin-induced asthma 
[23]. Antigen-induced bronchoconstriction is attenuated 
by prior treatment with leukotriene receptor antagonist 
[24, 25], supporting a role for the cysteinyl leukotrienes 
in acute allergic bronchoconstriction. The improvement 
in basal lung function after ingestion of an oral active 
LTD4 receptor antagonist [26], and improvement of pul­
monary lung function following long-term administra­
tion of leukotriene receptor antagonists [27], supports a
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role for the cysteinyl leukotrienes in influencing basal 
bronchial tone.
Residence at altitude may be beneficial for subjects 
with atopic asthma, possibly due to the low concentra­
tion of house dust mite antigen [28, 29]. A deteriora­
tion in lung function may be observed on return to sea 
level, and this has been attributed to the increased expo­
sure to allergen(s) and pollutants [28-31], This study 
involved asthmatic children who were resident at The 
Netherlands Asthma Centre at altitude, since it had been 
observed that a return to The Netherlands may be ac­
companied by a deterioration in lung function.
To assess whether the deterioration in lung function 
in atopic asthmatic subjects residing at altitude after 
transient exposure to low altitude is accompanied by 
elevations in urinary LTE4, we have measured urinary 
LTE4 in eight asthmatic subjects normally resident at 
altitude who returned to sea level for a short visit and 
six asthmatic subjects resident at altitude over a similar 
period of time.
Methods
Subjects
Fourteen asthmatic subjects were studied (table 1). 
Asthma was defined by a history of episodic wheezing 
and a >20% reversibility of resting FEVj following 400 
(ig inhaled albuterol. Atopic asthmatic subjects demon­
strated a >3 mm wheal as compared to the diluent con-
Table 1. -  Subject characteristics
Subject Age Sex Atopy FEVj TX
No. yrs % pred
Asthmatic subjects returning to The Netherlands
1 15 M + 93 A
2 15 M + 87 AB
3 15 F + 92 ABD
4 13 F + 115 AB
5 15 M + 106 AB
6 12 F + 109 AB
7 12 M + 83 AC
8 15 F + 100 ABC
Mean 14 98.1
SEM 0.5 3.9
Asthmatic subjects remaining in Davos
9 16 M + 115 AB
10 14 F + 121 AB
11 16 M + 92 AB
12 14 M + 91 AB
13 15 M + 107 AB
14 15 F + 53 AB
Mean 15 96.5
SEM 0.3 9.9
M: male; F: female; FEVp forced expiratory volume in 
one second; TX: treatment; A: inhaled albuterol; B: inhaled 
corticosteroid; C: cromoglycate; D: nedocromil. Mean is 
the arithmetic mean.
trol in response to skin-prick tests to at least two com­
mon aeroallergens: grass pollen, tree pollen, cat dander, 
dog hair, Dermatophagoides pteronyssinus and D. fari- 
me. All subjects were positive to house dust mite extracts. 
Subjects had not taken antihistamines in the month prior 
to the study, and no subject had experienced an upper 
respiratory tract infection in the preceding month, or 
during the study. The study protocol was approved by 
The Netherlands Asthma Centre Hospital Ethics Com­
mittee, and written informed consent was provided by 
the parent of each subject studied.
Study protocol
The Netherlands Asthma Centre in Davos is a clinic 
at moderate altitude (1,560 m). Asthmatic children may 
stay for up to 9 months and during this time return to 
The Netherlands for a short visit. In a prospective, ran­
domized fashion, mild asthmatic subjects who had been 
resident in The Netherlands Asthma Centre, Davos, 
Switzerland (1,560 m) for at least one month, were selec­
ted to participate in the study following a full clinical 
history, examination and skin-prick tests to common 
inhaled aeroallergens. Subjects were randomly divided 
into two groups. During the same month, one group 
remained in Davos, whilst the second group returned to 
The Netherlands (360 m) for 14 days and then returned 
to Davos. All subjects attended the laboratory on two 
separate study days at the same time of day. In asth­
matic subjects who remained in Davos, the study days 
were separated by 3 weeks, whereas in the group of asth­
matic subjects who returned to The Netherlands, the study 
days were performed within 48 h of leaving for The 
Netherlands and within 48 h of returning to Davos. 
Medication was withheld for 8 h prior to each study 
day. On each study day, blood was withdrawn for total 
IgE measurement and eosinophil count. A urine sample 
was collected for LTE4 measurement, and then, within 
one hour, a histamine inhalation challenge was perfor­
med. Two subjects refused blood sampling on the sec­
ond study day, One further subject selected in addition 
to the 14 participating in the study was excluded from 
the study, since medication was altered between the 2 
study days when the subject returned to The Netherlands 
and maintenance therapy with steroids was changed. 
There was no change in medication between the two 
study days in the other asthmatic subjects studied.
Histamine inhalation challenge was performed using 
the Asthma Provocation System (APS) dosimeter (Jaeger, 
Wuzzburg, Germany), which delivers compressed air at 
a pressure of 1.6 bar (22.8 psi) for a duration of 0.6 s 
from the start of each breath. Under these conditions, 
the nebulizer delivers droplets with a mass median aero­
dynamic diameter of 1.9 |jm. The output of the nebuli­
zer is 9.3 lil-breath*1. Measurements of FEVj were made 
using a Jaeger Masterlab Spirometer. Three measure­
ments of ¥EV{ were made at each time-point and the 
mean value was recorded. Provided baseline FEVl was 
greater than 70% predicted for the patient, inhalation 
challenge proceeded. Each inhalation started at functional
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residual capacity and terminated at approximately 70% 
baseline vital capacity; a 5 s breathhold was maintained 
at the end of each inhalation. Subjects inhaled control 
solution (five breaths of normal saline). FEVj mea­
surements were made at 1 and at 3 min after each inhala­
tion. If the decrease in FEV, was <10% baseline value, 
subjects underwent inhalation challenge with histamine. 
Serial twofold increasing concentrations of histamine 
diphosphate (Leiden University Hospital, Leiden, The 
Netherlands) were inhaled from a concentration of 0.03 
mg'inl-1 up to a maximum concentration of 32 mg-ml*1. 
Doubling concentrations of histamine were administered 
until the FEV, had fallen by >20% baseline value. The 
provocation concentration of histamine producing a 20% 
fall in FEV, (PC20FEVj) was determined from the log 
concentration histamine response curve by linear inter­
polation.
a) b)
Measurement o f urinary LTE4
Urine was collected prior to inhalation of histamine. 
The volume of urine was recorded and a 50 ml aliquot 
saved. The free radical scavenger, 4 hydroxy-2,2,6,6- 
tetramethyl-l-piperidino-oxy free radical (4-hydroxy 
TEMPO; Aldrich Chemical Co., Milwaukee, WI, USA) 
was added at a final concentration of 1 mM, and the 
samples adjusted to pH 9.0 with NaOH to stabilize en­
dogenous leukotriene metabolites. The samples were 
coded and stored at -70°C until measurements of LTE4 
were performed by RP-HPLC and RIA, as described pre­
viously [17].
>
Study 
Day 1
Study 
Day 2 Day 1 Day 2
Fig, 1. -  The FEVj on study day one and two in individual asth­
matic subjects: a) returning to The Netherlands; or b) resident in 
Davos. Bars indicate arithmetic mean. FEV,: forced expiratory vol­
ume in one second.
Statistical analysis
in subjects returning to The Netherlands and those sub­
jects remaining in Davos, respectively.
In the group of subjects who returned to The Nether­
lands, there was a significant decrease in FEVj on return 
to Davos from 3.0±0,3 to 2.8±0.3 I (mean±sEM) (p=0.04). 
In subjects who remained in Davos, there was no sig­
nificant difference in FEV! which was 2.9+0.3 and 2.9± 
0.4 / (p=0.35) on study day one and study day two, 
respectively (fig. 1 and table 2).
Values for urinary LTE4 and PC20FEV, histamine were 
logarithmically transformed prior to analysis, and the 
results were expressed as geometric mean (gm). For 
PC20FEV, histamine, statistical analysis was only per­
formed on subjects in whom a PC20FEV, histamine was 
determined. The Wilcoxon samples test was used to 
compare FEV1? urinary LTE4 and PC20FEV, histamine 
between the two groups of subjects on study day one, 
and the changes in FEVP urinary LTE4, PC20FEV, his­
tamine, total IgE, and eosinophil count between study 
day one and two in each group of asthmatic subjects. 
The relationship between urinary LTE4 and FEVj, PC20FEVj 
histamine, total IgE and eosinophil count in the subjects 
was analysed using Pearsons correlation coefficient.
Results
Lung function
The FEV, values for individual subjects in the two 
groups on study day one are shown in figure 1 and table 
2. There was no significant difference between the base­
line FEV, in the two groups of asthmatic subjects stud­
ied, being 3.0±0.3 / (mean±SEM) and 2.9±0.3 / (p=0.9)
Airway response to histam ine
The PC20FEVj histamine in individual subjects on the 
two study days are shown in figure 2 and table 2. Sub­
ject No. 7 (study day 1) and No. 8 (study day 1 and 2) 
(table 2) did not respond with a 20% fall in FEV, after 
the maximum dose of histamine was administered. Hista­
mine challenge was not performed in subject No. 14 
because he had a resting FEV, <65% of predicted FEV, 
on study day one and two. There was no significant dif­
ference in PC20FEV, histamine on study day one bet­
ween the two groups of asthmatic subjects. The PC20FEV, 
histamine was 1.7 mg-ml*1 (gm, range 0.3-16.4 mg-ml*1) 
(n=5) and 1.5 mg-mh1 (gm, range 0.3-22 mg-ml-1) (n=5) 
(p=0.5) in asthmatic subjects returning to The Netherlands 
and those subjects remaining in Davos, respectively. 
There was a significant decrease in PC20FEV, histamine 
from 1.7 mg-ml'1 (gm, range 0.3-16.4 mg-ml*1) to 0.9 
mg-ml*1 (gm, range 0.1-5.2 mg-ml"1) (p=0.04) (n=5) fol­
lowing a 14 day visit to The Netherlands. In subjects 
who remained in Davos, there was no significant dif­
ference in PC20FEV, histamine, which was 1.5 mg-ml*1 
(gm, range 0.3-22 mg-ml-1) and 1.5 mg-ml4 (gm, range
0.3-32 mg-ml1) (p=0.89) (n=5) on study day one and 
two, respectively.
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Table 2. -  The FEV^ PC20FEVT histamine and urinary LTE4 in asthmatic subjects on the two study days
Subject
No.
FEV,
I
PC20FEV, histamine 
mg-rnl-1
LTE4 
pg-mg-1 creatinine
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Asthmatic subjects returning to The Netherlands
1 2.6 2.3 16.4 5.2 37.0 130.0
2 3.8 3.2 1.0 0.4 0.3 8.8
3 2.2 2.0 0.3 0.1 40.2 173.6
4 4.6 3.3 1.5 1.3 19.6 14.0
6 2.1 1.9 0.8 0.6 101.7 301.6
7 2.5 2.4 >32.0 13.0 11.3 46.3
8 2.8 2.8 >32.0 >32.0 25.7 134.0
Mean 3.0 2.8 1.7 0.9 16.9 52.3
SEM 0.3 0.3
Asthmatic subjects remaining in Davos
9 3.8 3.8 0.3 0.6 10.6 11.7
10 3.0 2.8 1.3 0.7 5.9 5.1
11 3.1 2.8 0.3 0.3 9 4 8.1
12 2.5 2.6 22.0 32.0 14.0 22.0
13 4.0 4.1 2.4 2.0 41.9 25.0
14 1.4 1.2 ND ND 33.0 13.0
Mean 2.9 2.9 1.5 1.5 14.9 12.0
SEM 0.3 0.4
LTE4: leukotriene E4: PCaoFEVj: concentration of histamine producing a 20% decrease in FEV,; ND: not determined. The 
mean for FEVj is the arithmetic mean. The mean for PC2oFEV1 histamine is the geometric mean of subjects with a PC20FEV, 
histamine (subjects Nos. 1-6). The mean for LTE4 concentration is the geometric mean. For further abbreviations see legend to 
table 1.
Urinary LTE4 concentration
There was no significant difference between the uri­
nary LTE4 concentration on study day one between the 
two groups of asthmatic subjects. The LTE4 concentra­
tion was 16.9 pg-mgA creatinine (g m , range 0.3-101.7
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pg-mg-1 creatine) and 14.9 pg-mg-1 creatinine (g m , range 
5.9-41.9 pg‘mg ‘ creatinine) (p=0.6) in asthmatic sub­
jects returning to The Netherlands and remaining in 
Davos, respectively.
There was a significant increase in urinary LTE4 con­
centration in the group of subjects returning to Davos 
from The Netherlands, from a baseline value of 16.9 
pg-mg*1 creatinine (g m , range 0.3-101.7 pg-mg-1 creati­
nine) to 52.3 pg-mg*1 creatinine (g m , range 8.8-301.6 
pg-mg-1 creatinine) (p=0.04) (fig. 3 and table 2). In con­
trast, there was no significant difference in urinary 
LTE4 concentration in subjects resident in Davos, whose 
urinary LTE4 concentration on study day 1 and 2 were 
14.9 pg*mg-1 creatinine (g m , range 5.9-41.9 pg-mg1 cre­
atinine) and 12.0 pg-mg1 creatinine (g m , range 5.1-25 
pg-mg-1 creatinine) (p=0.24), respectively.
0.0
p=0.04
Study Study 
Day1 Day 2
0.0
p=0«89
Study Study 
Day 1 Day 2
Fig. 2. -  The PC20FEV, histamine on study day 1 and 2 in individ­
ual asthmatic subjects: a) returning to The Netherlands; or b) resi­
dent in Davos. Bars indicate geometric mean. PC20FEVP provocative 
concentration of histamine producing a 20% decrease in forced expi­
ratory volume in one second.
IgE and eosinophil count
The total IgE level and eosinophil count in individual 
subjects is shown in table 3. There was no significant 
difference in total IgE levels or eosinophil counts in 
either group of subjects studied.
There was no significant correlation between urinary 
LTE4 and FEVj (r=0.25, p=0.19; r=-0.5, p=0.91), urinary 
LTE4 and PC20FEV, histamine (r=0.08, p=0.48; r=<0.01, 
p=0.97), urinary LTE4 and eosinophil count (r=0.18, 
p=0.26; r=<0.01, p=0.87), and urinary LTE4 and total 
IgE level (r=02, p=0.26; r=0.146, p=0.45) in asthmatic 
subjects returning to The Netherlands or resident in Davos, 
respectively.
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a) b)
Study Study Study Study
Day1 Day 2 Day1 Day 2
Fig. 3. -  The urinary LTE4 concentration on study day 1 and 2 in 
individual asthmatic subjects: a) returning to The Netherlands; or b) 
resident in Davos. Bars indicate geometric mean. LTE4: leukotriene
Table 3. -  Total IgE and eosinophil counts in subjects 
studied
Total IgE Eosinophils
kU-/*1 xlO6*/-1
Subject
No. Day 1 Day 2 Day 1 Day 2
Subjects returning to The Netherlands
1 572 947 531 866
2 1330 1100 122 559
3 295 339 94 169
4 557 543 3 0
5 3515 4310 288 113
6 233 271 397 297
7 2845 2930 222 125
8 5010 6150 241 497
Mean 1794 2073 237 328
SEM 631 796 60 102
Subjects remaining in Davos
9 675 570 334 256
10 3960 4005 1012 563
11 814 ND 134 ND
12 1090 858 406 278
13 1142 1077 497 550
14 722 ND 741 ND
Mean 1400 1627 520 411
SEM 517 799 127 837
Mean is the arithetic mean. IgE: immunoglobulin E; Sub: 
subject; ND: blood sample refused by subject.
Discussion
This study demonstrates that in 6 out of 8 allergic asth­
matic children resident at altitude who returned briefly 
to sea level and then returned to altitude, there was a 
decline in baseline FEV, and an increase in airway res­
ponsiveness to histamine. These changes were accom­
panied by an increase in urinary LTE4 excretion. The 
range of LTE4 concentration on study day one in our 
subjects was similar to that observed previously in adult 
asthmatic subjects [20, 32], suggesting that there is no 
age-related difference in the range of LTE4 concentra­
tion during stable asthma and in the absence of other 
disease. A raised baseline urinary LTE4 is suggestive of 
aspirin-sensitive asthma [23], but there was no clinical 
history of aspirin sensitivity or other distinguishing clini­
cal features in subject No. 6 who had a baseline urinary 
LTE4 higher than the other subjects.
After a 2 week stay in The Netherlands, LTE4 excre­
tion increased up to approximately threefold, in associ­
ation with a decrease in baseline FEV, and an increase 
in airway reactivity to histamine. This was not observed 
in subjects Nos. 4 and 5, who did not demonstrate a 
change in FEV! or PC20FEV, histamine between the two 
study days. The cause of this heterogeneity in response 
is unknown, but may reflect the variation of reactions in 
asthmatic subjects to environmental factors. Medication 
was withheld for 8 h prior to FEV, measurements, urine 
collections and histamine challenge and there was no 
change in medication between the two study days. In 
healthy subjects, R ic h a l e t  et al. [33] observed that acute 
altitude hypoxia is associated with an increase in plas­
ma LTB4. An increase in leukotriene excretion during 
acute asthma in adult subjects has been reported by 
T a y l o r  et a i [19]. A threefold increase in leukotriene 
excretion has also been reported following antigen and 
aspirin challenge in asthmatic subjects [19, 23].
LTE4 concentration may be used to reflect systemic 
and pulmonary release of cysteinyl leukotrienes [31]. 
The increase in leukotriene excretion during a deterio­
ration of lung function reflects an increase in cysteinyl- 
leukotriene biosynthesis. The cysteinyl leukotrienes may 
have a central role in the pathogenesis of asthma, as sug­
gested by their recovery from the bronchoalveolar fluid 
of asthmatic subjects [32], activity as potent lung spas- 
mogens, and ability to increase airway hyperresponsive­
ness [10-12]. Their presence may explain the decrease 
in lung function and increase in airway responsiveness 
to histamine observed in our subjects after a brief visit 
to The Netherlands. Consistent with prior studies, we 
were unable to correlate circulating mediator levels of 
leukotrienes, FEV, measurement or airway reactivity to 
histamine [32]. At altitude, the concentration of house 
dust mite allergen is reduced [27, 30], and it has been 
suggested that it is the decreased exposure to house dust 
mite which accounts for the improvement of lung func­
tion in allergic asthmatic subjects after a stay at altitude. 
All our subjects were sensitive to house dust mite aller­
gen on skin-prick testing, and it is possible that increased 
allergen exposure to house dust mite after return to sea 
level resulted in the deterioration of lung function. Other 
allergens and irritants, such as pollutants and other fac­
tors which change with altitude (humidity, temperature, 
barometric pressure), should also be considered. There 
was no difference in total IgE level between the two 
study days in subjects returning to The Netherlands, 
although changes may not be apparent during this short
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period of time. Whilst specific IgE against house dust 
mite was not determined during the study period in our 
subjects, dust mite allergen concentration from bedrooms 
at the Asthma Centre in Davos is low and in the region 
of 18 ng‘g~* dust.
We did not detect a difference in blood eosinophil 
counts in subjects returning to The Netherlands. This is 
similar to the study of B o n e r  et al. [34], where the influ­
ence of allergen avoidance at altitude on serum markers 
of eosinophil activation in children with allergic asthma 
was investigated. Whilst there was no increase in peri­
pheral eosinophil count during allergen exposure, there 
was activation of eosinophils as indicated by the increase 
of eosinophil cationic protein (ECP) and eosinophil 
protein X (EPX) serum markers. It is possible that part 
of the increase in cysteinyl leukotrienes was due to eosi­
nophil activation during exposure to allergen in subjects 
returning to The Netherlands. The involvement of other 
cells, such as monocytes or mast cells, as a source for 
leukotriene synthesis was not determined in this study.
With the exception of subject No. 14, on study day 
one, all subjects had controlled asthma with FEVt mea­
surement >70% of predicted. A decrease in FEV1 mea­
surement was not observed in all subjects returning to 
Davos from The Netherlands. Whilst clinical severity 
could have been additionally assessed using peak flow 
readings and symptom scores, this was not possible due 
to poor compliance with completing peak flow charts 
and symptom questionnaires in the subjects. In this 
regard, parents were questioned about any changes in 
medication during the study period. Airway reactivity 
was assessed using PC20FEVj histamine, which is used 
routinely in The Netherlands Asthma Centre. In sub­
jects Nos 7 and 8, airway reactivity to histamine on study 
day one was >32 mg-mH These subjects had a history 
of asthma and a PC20FEVj histamine <8 mg-ml'1 on ad­
mission to the clinic 4 weeks prior to the study. An im­
provement in lung function and airway reactivity within 
a week of residence at altitude has previously been ob­
served in altitude clinics. For this reason, the study was 
conducted after the subjects had been resident for one 
month at altitude, to optimize stable control of asthma.
In conclusion, utilizing a novel design to provoke 
a minor deterioration in asthma through a change in 
the natural environment, we have demonstrated that a 
decrement in FEVl and an increase in airways respon­
siveness are accompanied by augmented biosynthesis of 
the cysteinyl leukotrienes. These results add further sup­
port to the need to test leukotriene receptor antagonists 
or biosynthesis inhibitors in the treatment of asthma.
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